Compare Simon Property Group Inc (SPG) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Simon Property Group Inc vs TransMedics Group Inc — how do they compare? Simon Property Group Inc trades at $219.28 (market cap $71.03B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Simon Property Group Inc is far larger — about 22.9× TransMedics Group Inc's market cap, and Simon Property Group Inc pays a 4.05% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| SPG | TMDX | |
|---|---|---|
Market Cap | $71.03B | $3.10B |
Sector | Real Estate | Technology |
52-Week High | $236.70 | $150.42 |
52-Week Low | $169.22 | $61.99 |
Enterprise Value | $99.48B | $3.49B |
Dividend Yield | 4.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Simon Property Group (SPG) trades at $220.31, down 0.11% on the day, with a bearish technical signal as price tests support near $218. The company reported strong Q2 2026 FFO of $3.29 per share, beating estimates, and raised full-year guidance, driven by robust leasing and retailer sales growth. Financials show high profitability with a net income margin of 66.57% and ROE of 135.7%, though valuation ratios like P/S of 10.29 and P/B of 16.16 appear elevated.
Outlook remains positive with analyst consensus favoring a Buy rating and a $226.58 price target, supported by operational strength and dividend reliability. Key risks include high leverage with $24.21B in long-term debt and sensitivity to interest rates. Earnings growth and strategic acquisitions present upside, but macroeconomic headwinds could pressure retail real estate demand.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
